1,559 results on '"Katzenellenbogen, John A."'
Search Results
2. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer
3. [18F]Tosyl fluoride as a versatile [18F]fluoride source for the preparation of 18F-labeled radiopharmaceuticals
4. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs
5. Somatic estrogen receptor [alpha] mutations that induce dimerization promote receptor activity and breast cancer proliferation
6. FOXM1 regulates glycolysis and energy production in multiple myeloma
7. Dual-mechanism estrogen receptor inhibitors
8. Solid phase radiosynthesis of an olaparib derivative using 4-[18F] fluorobenzoic acid and in vivo evaluation in breast and prostate cancer xenograft models for PARP-1 expression
9. Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor β ligand-induced remyelination in a mouse model of multiple sclerosis
10. Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis.
11. Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination
12. Asymmetric Allostery in Estrogen Receptor-α Homodimers Drives Responses to the Ensemble of Estrogens in the Hormonal Milieu
13. Abstract B010: Development of folate receptor alpha targeted FOXM1 inhibitors for ovarian cancer
14. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression
15. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells
16. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review
17. Asymmetric allostery in estrogen receptor-a homodimers drives responses to the ensemble of estrogens in the hormonal milieu.
18. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.
19. Reprogramming of endothelial gene expression by tamoxifen inhibits angiogenesis and ERα-negative tumor growth
20. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer
21. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer
22. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy
23. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors
24. Multiple functional therapeutic effects of the estrogen receptor β agonist indazole-Cl in a mouse model of multiple sclerosis
25. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer
26. OR11-01 A New Model for Estrogen Receptor-alpha Antagonist Mechanism of Action
27. Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors
28. A chiral pool approach for asymmetric syntheses of both antipodes of equol and sativan
29. Directed Evolution of Specific Receptor-Ligand Pairs for Use in the Creation of Gene Switches
30. Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice
31. Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies
32. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds
33. In Vivo and in Vitro Steroid Receptor Assays in the Design of Estrogen Radiopharmaceuticals
34. Evidence that Phospholipase A 2 Activity is Required for Golgi Complex and Trans Golgi Network Membrane Tubulation
35. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
36. Abstract 3984: NB compound FOXM1 inhibitors have potent anti-cancer activity in high-grade serous ovarian carcinoma
37. Data from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
38. Supplementary Figures 1 - 8, Tables 1 - 3 from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
39. Supplementary Methods from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
40. Data from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
41. Supplementary Figures_S1-S6 from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
42. Data from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
43. Supplementary Figure 1 from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
44. Supplementary Figure Legends from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
45. Data from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
46. Supplementary Table 1 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
47. Supplementary Figure 3 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
48. Supplementary Figure 2 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
49. Supplementary Figure 1 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
50. Supplementary Figure 5 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.